Heather N. Sugrue will serve as the company’s vice-president of Business Development.
Tergus Pharma, a US-based contract development and manufacturing organization (CDMO), announced on March 1, 2021 that Heather N. Sugrue will serve as the company’s vice-president of Business Development.
Prior to her new role at Tergus, Sugrue spent three years at Recro as the vice-president of sales and marketing and six years with Patheon Pharmaceuticals as the senior director of business development for the West Coast, Tergus said in a company press release. Before working at Patheon, Sugrue was employed at Ricerca Biosciences where she supported investigational new drug (IND)-enabling services from lead optimization through IND submission.
“Heather will play a critical role in Tergus’ growth in 2021 and beyond,” said Tergus Pharma chairman and CEO, Dr. Vijendra Nalamothu, in the press release. “Her breadth and depth of sales and business development in the CDMO space will be vital to managing and sustaining our commercial manufacturing expansion while we also maintain our leadership role in topical development. Under Heather’s leadership, Tergus will be expanding the sales team to focus on the growing needs of topical manufacturing in prescription brand and generic manufacturing as well as [over-the-counter] drug product manufacturing.”
Source: Tergus
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.